Collegium Pharmaceutical Inc expected to post earnings of 73 cents a share - Earnings Preview

Collegium Pharmaceutical

08/05/2024 03:22

* Collegium Pharmaceutical Inc  COLL.OQ   COLL.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 9 for the period ending March 31 2024
    * The Stoughton Massachusetts-based  company is expected to
report
a 1.4% increase in revenue to $146.853 million from $144.77
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Collegium Pharmaceutical
Inc
is for earnings of 73 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 14.8%
in the last three months. ​
    * Wall Street's median 12-month price target for Collegium
Pharmaceutical Inc is $40.00​, above​ its last closing price
of $37.30. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  0.64        0.66       0.82      Beat    24.2
 Sep. 30 2023  0.51        0.52       0.53      Beat    2.6
 Jun. 30 2023  0.28        0.29       0.34      Beat    18.3​
 Mar. 31 2023  0.26        0.31       -0.51     Missed  -262.4
 ​​Dec.        -0.04       -0.14      -0.21     Missed  -44.8
 31 2022                                                
 Sep. 30 2022  -0.19       -0.13      0.01      Beat    107.4​
 Jun. 30 2022  1.38        1.42       0.32      Missed  -77.5
 Jan. 1 0001   0.90        0.90       0.44      Missed  -50.9
 This summary was machine generated May 8 at 02:22 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)